Ignite Creation Date:
2024-05-06 @ 3:16 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04578444
Status:
AVAILABLE
Last Update Posted:
2024-04-23
First Post:
2020-09-30
Brief Title:
An Expanded Access Treatment Protocol of Zanidatamab ZW25 in Patients With HER2-Positive Advanced Biliary Tract Cancer
Sponsor:
Jazz Pharmaceuticals
Organization:
Jazz Pharmaceuticals
Study Overview
Official Title:
Expanded Access Use of Zanidatamab for the Treatment of HER2-Positive Advanced Solid Tumor
Status:
AVAILABLE
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an intermediate-size Expanded Access Protocol EAP for use of zanidatamab ZW25 in patients with human epidermal growth factor receptor 2 HER2-positive advanced biliary tract cancer BTC who are not eligible for other zanidatamab clinical trials and who in the opinion of the treating oncologist would potentially benefit from treatment with zanidatamab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None